Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma - Wikidata - wikimedia - TriplyDB

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma

http://www.wikidata.org/entity/Q36403491

about

Non-surgical interventions for late rectal problems (proctopathy) of radiotherapy in people who have received radiotherapy to the pelvis Aminosalicylates for induction of remission or response in Crohn's disease Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity Aminosalicylates for induction of remission or response in Crohn's disease PPARγ and the Innate Immune System Mediate the Resolution of Inflammation Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease Classical and recent advances in the treatment of inflammatory bowel diseases Mesalamine in the treatment and maintenance of remission of ulcerative colitis Role of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer.Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases Review article: maintenance therapy in patients with ulcerative colitis Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1 Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling Inflammatory bowel disease Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work.Drugs in development for influenza.SAMP1/YitFc mouse strain: a spontaneous model of Crohn's disease-like ileitis.Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression.The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelity.Oral administration of mesalazine protects against mucosal injury and permeation in dextran sulfate sodium-induced colitis in rats.Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage-mediated fungal clearance during Pneumocystis pneumonia.A Systems Pharmacology Approach to Determine Active Compounds and Action Mechanisms of Xipayi KuiJie'an enema for Treatment of Ulcerative colitis.Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.Induction of Colonic Regulatory T Cells by Mesalamine by Activating the Aryl Hydrocarbon Receptor Mesalazine in inflammatory bowel disease: a trendy topic once again?New Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and Adherence Is there a biological basis for treatment of fibrodysplasia ossificans progressiva with rosiglitazone? Potential benefits and undesired effects.Colon OCTN2 gene expression is up-regulated by peroxisome proliferator-activated receptor gamma in humans and mice and contributes to local and systemic carnitine homeostasis Gastrointestinal Cytoprotection by PPARγ Ligands.A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis.Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids Pharmacological and non-pharmacological interventions to influence adipose tissue function.β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway.Peroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitis.Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease

P2860

Q24185868-40286547-7FAC-4B0F-AA28-A257A46FE739 Q24235730-238DCB09-E973-4554-9498-4C59A300FB15 Q24322799-8173BC56-065B-4CC5-BF16-836A887B91D8 Q26471183-6605EF07-2112-498C-95E5-09BF0B03E3C6 Q26771755-2CB3110B-9D34-4D17-8E55-BA9280004A16 Q26777634-5612A32D-FEE0-4FB5-BB62-A593F8CF5DE1 Q26786018-DDE8E958-F72F-491B-BC1D-93925776AE64 Q26851490-123CE93B-E00D-4F3D-A32B-29C462D0D4CE Q26861725-5C371D57-555F-44A2-9145-74CE986B25C1 Q26865546-CE2B58C2-673B-4BC9-B18C-8FA7CF4BF9FC Q27022548-577F3F3E-3134-4AB8-9519-0ED969E3E014 Q27687166-EE860D3B-BEBD-4B3E-830D-8A8565FFD256 Q28071309-95485134-FB44-4FD1-B51A-7075265E7567 Q28260710-3C8CFA37-32D5-44E7-B45C-E89FBD7660BC Q28279134-63B19974-021F-4114-AF78-0E7FE32B0268 Q28553419-0DB146C4-07A9-4D26-813D-04F9C8B7B6AB Q28596448-90F4A91B-EC65-4E9A-A1DF-FF0BD6DC9C70 Q29615500-1DF5B9FC-6EF5-42C5-8E51-A1CAB7229722 Q30379206-0DC5A600-71AA-4084-9546-4F62129CEE94 Q30391218-F00E4AFA-34CB-4489-9AC4-C730CC3AF4E6 Q30423660-3335CEB0-4165-4680-A7F5-FDBDBC91EB8C Q30440147-5538BFE7-BCA4-4823-B4C0-B7912D285555 Q33406895-DBC0B32F-52B7-4671-A484-9960DBDA71B0 Q33509847-F7047967-AF36-44F6-BE72-0F8531BC978C Q33515113-1B236372-B269-4E83-AC3F-3FFB385C4F51 Q33680480-8AA4F016-0FFF-4BDE-BF36-5C7730BEE21F Q33681862-D7EF2A5C-BF0C-423D-B9A7-878E9D551868 Q33701611-A33792ED-BFA6-4464-8C08-4151A572A786 Q33752706-CA8AC61A-6B69-447B-B291-8F7DB9DF16E8 Q33779797-F3DDF649-D6A8-49DF-89CE-3ACFD2A6A08B Q33916287-415645F3-6B8A-4B84-AEC5-29A1F43A41C3 Q33960879-F88855A4-F001-43DE-84A5-335C0ECD0359 Q34094462-ED38F390-1E37-45DF-9B7E-BDA8A2CEFD6F Q34159427-8E0FCEBD-8729-4C37-BC26-C8AF1C97D2CC Q34178953-D37127FA-5790-42C1-A110-937725077EF7 Q34291196-7A5169F7-AC39-407D-AE57-F5D4536C7343 Q34576535-2AA2BE21-A628-4D84-819A-E4CF14050714 Q34760736-3C26758F-F35D-423F-B4BC-0E64F6C84B5A Q34762999-0EBA2776-D081-403D-8C50-E2E2CDD92B75 Q34804346-CA395022-A18A-4054-AD33-1E3745F3F023

P2860

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma

http://www.wikidata.org/entity/Q36403491

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Intestinal antiinflammatory ef ...... rator-activated receptor-gamma

@ast

Intestinal antiinflammatory ef ...... rator-activated receptor-gamma

@en

type

label

Intestinal antiinflammatory ef ...... rator-activated receptor-gamma

@ast

Intestinal antiinflammatory ef ...... rator-activated receptor-gamma

@en

prefLabel

Intestinal antiinflammatory ef ...... rator-activated receptor-gamma

@ast

Intestinal antiinflammatory ef ...... rator-activated receptor-gamma

@en

P1433

Q36403491-3C6D6DE9-A218-456F-A02E-9A1297BDADA8

P1476

Q36403491-23F2FDC7-51BF-49AD-A77E-1AE61449B5F8

P2093

Q36403491-07FF7C7F-252C-4FE6-8673-B8EC01E99EC0

Q36403491-13E3014E-C722-4A7A-87AE-EAAFAE7638C6

Q36403491-1D75A4EB-E9EC-41E3-9A32-B84332BF0F4B

Q36403491-5CA55B8D-B13D-45E9-B477-254F48D114A2

Q36403491-89637AD2-A751-46C3-A1DF-32C128AE029E

Q36403491-915CBC40-79EA-415C-A718-0401466EB511

P2860

Q36403491-09520B40-C625-4992-B125-B40AACB1A5B9

Q36403491-0BD4B8D2-1148-4DAC-9AFB-004F3011278F

Q36403491-0FA7666A-3EDF-4067-BE06-A9C948E872A4

Q36403491-129CBE17-AC27-4AF6-B66B-EA7B0402696E

Q36403491-1D5D0F38-571E-4134-84EB-89F2CA7B4C7F

Q36403491-201D094C-5616-4674-8681-6B89CF84E144

Q36403491-21021B1F-BFCD-4F64-9D87-D21F3FB8E9DD

Q36403491-323E2908-6D7A-4D72-BA6C-93AF024CCD19

Q36403491-364F09B7-9BC4-4A68-B9CF-B34EDD349675

Q36403491-3754ADCD-CE17-410F-B948-09DD5A1CB431

P304

Q36403491-8586916B-7300-4027-821A-0372E6AA85B2

P31

Q36403491-F93CE083-A288-4AC4-9046-E31422E0493A

P356

Q36403491-C70468D4-7640-4502-ACC5-82D62CCC1332

P407

Q36403491-923A3536-D213-4D74-A4CE-06E0336A9D23

P433

Q36403491-FB6AB218-5F48-48B9-A1E0-18AAFBDAAE6F

P478

Q36403491-CD3C35BA-BABB-41CC-B73A-9442C9DF7AE5

P50

Q36403491-5864294A-1308-4718-8DE5-C1AC9C475A02

Q36403491-71E813AC-6350-496D-AA9E-C24C4C75B5E7

Q36403491-972F29AE-D1EC-4110-8CF6-49C0F4E9B311

Q36403491-9FA31B0D-0E47-4F0E-AACB-C861E428CAA0

Q36403491-ADF8791B-F2FA-4019-A196-944B451B3990

Q36403491-BEF43A73-A6FD-4552-B4E2-DA31C16D24AF

Q36403491-C42A0763-C5B9-4E3F-943D-AF5A0F8D4815

Q36403491-CACA9734-6020-4E4F-A5D9-96455BF2C0AA

Q36403491-E6E9EFA2-822D-494F-904E-61A5566B24D2

Q36403491-FDB43220-9DB2-4BC9-88C5-1AD218494E61

P577

Q36403491-F7DB604B-446E-4AFE-AE1D-54D43182F741

P5875

Q36403491-1E8E11BE-E95D-4097-98DD-6AACD67BA0B5

P698

Q36403491-16F04823-0166-4E37-B2B1-BD1F2BDD60E1

P932

Q36403491-94FF99F7-A78F-4469-9243-F7A202F1FB47

P356

P1433

Journal of Experimental Medicine

P1476

Intestinal antiinflammatory ef ...... rator-activated receptor-gamma

@en

P2093

Christel Rousseaux

http://www.w3.org/2001/XMLSchema#string

Gian Carlo Naccari

http://www.w3.org/2001/XMLSchema#string

Olivier Romano

http://www.w3.org/2001/XMLSchema#string

Philippe Bulois

http://www.w3.org/2001/XMLSchema#string

Philippe Lefebvre

http://www.w3.org/2001/XMLSchema#string

Walter Wahli

http://www.w3.org/2001/XMLSchema#string

P2860

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis

Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors

Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma

The nuclear receptor superfamily: the second decade

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Development and validation of a genetic algorithm for flexible docking

The organization, promoter analysis, and expression of the human PPARgamma gene

Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor

A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat

P304

1205-1215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20041948

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

201

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Frédéric Colombel

Béatrice Desvergne

Laurent Dubuquoy

Philippe Chavatte

Pierre Desreumaux

P577

2005-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7912968

http://www.w3.org/2001/XMLSchema#string

P698

15824083

http://www.w3.org/2001/XMLSchema#string

P932

2213148

http://www.w3.org/2001/XMLSchema#string